Pfizer/Ligand's Lasofoxifene Is First "Next-Generation" SERM Filed At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA for the selective estrogen receptor modulator has an estimated user fee date of June 2005 for post-menopausal osteoporosis prevention indication. Drug could offer benefits over Lilly's SERM Evista, Ligand says.